Mode
Text Size
Log in / Sign up

Higher baseline PANSS negative symptom severity associated with lower risk of symptom exacerbationHigher Baseline Negative Symptoms Linked to More Stable Schizophrenia Course

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that higher baseline negative symptom severity is associated with a lower risk of short-term symptom exacerbation.

This randomized controlled trial included 1139 adults aged 18 to 65 years meeting DSM-IV criteria for schizophrenia. The study analyzed the relationship between baseline PANSS negative symptom tertiles and the time to exacerbation, defined as a 12-point increase from baseline on the PANSS total score over an 18-month follow-up period.

Participants in the medium negative symptom group showed a reduced exacerbation risk (HR = 0.72; p < 0.04). Similarly, participants in the high negative symptom group showed a reduced exacerbation risk (HR = 0.70; p < 0.04). Overall, 25.5% of participants experienced exacerbation during the study period.

Safety data, including adverse events and tolerability, were not reported. A noted limitation is that prior findings have been inconsistent due to small samples, infrequent assessments, and non-standardized measures. Clinicians should note that while higher baseline negative symptom severity is associated with a lower likelihood of short-term symptom worsening, this does not imply a lower functional burden for these patients.

How this fits prior evidence

How this fits prior evidence: This finding addresses a gap in understanding the stability of illness courses in schizophrenia. While prior coverage noted that aerobic exercise combined with tai chi may reduce Positive and Negative Syndrome Scale scores, this study specifically examines the impact of baseline negative symptom severity on the risk of symptom exacerbation. It provides a different perspective on the stability of the condition rather than the efficacy of specific interventions like exercise or pharmacological options like semaglutide and liraglutide for weight management.

Researchers conducted a large study involving 1,139 adults with schizophrenia to see how initial symptoms affect the course of the illness. They specifically looked at negative symptoms, which are things like social withdrawal or lack of motivation, and tracked how long it took for patients to experience a significant worsening of their condition.

The study found that patients who started with higher levels of these negative symptoms actually had a lower risk of experiencing a sudden flare-up over an 18-month period. This suggests that for some people with more severe initial symptoms, the illness may follow a more stable path in the short term.

It is important to note that a lower risk of flare-ups does not mean these patients have a lower burden of symptoms in their daily lives. Because previous research on this topic has been inconsistent due to small sample sizes, these results should be viewed as an association rather than a guarantee of a specific outcome.

What this means for you:
Higher initial negative symptoms in schizophrenia are linked to a lower risk of sudden symptom worsening over 18 months.

Common questions

What does a lower risk of exacerbation mean for patients?

A lower risk of exacerbation means that patients with more severe negative symptoms at the start of the study were less likely to experience a sudden, significant worsening of their symptoms over 18 months. However, this finding does not mean these individuals have a lower daily burden of symptoms or a better quality of life.

Who was included in this study?

The study included 1,139 adults between the ages of 18 and 65 who met the specific medical criteria for schizophrenia. Researchers tracked these patients for 18 months to observe how their symptoms changed over time.

Why was this study important for schizophrenia research?

Previous research on this topic has been inconsistent because of small sample sizes and non-standardized measures. This study used a large group of 1,139 people, providing a clearer look at how initial symptom severity relates to the stability of the illness course.

Study Details

Study typeRct
EvidenceLevel 2
Follow-up18.0 mo
PublishedSep 2026
View Original Abstract ↓
Understanding predictors of schizophrenia course is critical for long-term clinical management, yet prior findings have been inconsistent due to small samples, infrequent assessments, and non-standardized measures. Using data from phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), which includes a large cohort with monthly standardized evaluations, this study investigated whether baseline negative symptom severity predicts risk of symptom exacerbation over time. Participants were 1139 adults aged 18-65 years meeting DSM-IV criteria for schizophrenia. Symptoms worsening or exacerbation was defined as a ≥12-point increase from baseline on the PANSS total score. Cox regression survival models examined the association between baseline PANSS negative symptom tertiles and time to exacerbation, adjusting for age, sex, years since first prescribed antipsychotic medication, randomized antipsychotic treatment group, PANSS positive and general psychopathology subscales, and CGI-Severity. Overall, 25.5% of participants experienced exacerbation over an 18-month period of follow-up. Survival curves demonstrated significant separation across negative symptom tertiles (p < 0.05), with higher baseline negative symptoms associated with longer time to exacerbation. Compared with the lowest tertile, medium and high negative symptom groups showed reduced exacerbation risk (HR = 0.72 and HR = 0.70, respectively; both p < 0.04). Findings indicate that greater baseline negative symptom severity is associated with a lower likelihood of short-term symptom worsening, suggesting a relatively stable illness course among individuals with more severe negative symptoms. These results have implications for prognosis and treatment planning, while underscoring the persistent functional burden imposed by negative symptoms despite lower exacerbation risk.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.